The firm's revenues were aided by a $116.6 million contribution from Olympus Diagnostics, which the firm bought last year. It missed analysts' estimates and offered a disappointing forecast, sending its shares down sharply.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.